Form 4: ImmunityBio Director Wesley Clark Receives Stock Options

Director Wesley Clark was granted 65,600 stock options in ImmunityBio, Inc. as part of the company's 2025 Equity Incentive Plan.

Summary

• Director Wesley Clark received a grant of 65,600 stock options on June 9, 2026.
• The options have an exercise price of $7.25 per share.
• The award is subject to the 2025 Equity Incentive Plan.
• The options vest in full on the earlier of June 9, 2027, or the day before the next annual stockholders' meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future market performance of ImmunityBio common stock exceeding the $7.25 exercise price.

Future Outlook

The options vest in one year, signaling a retention incentive for the director through the next annual meeting cycle.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure director commitment and alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard corporate governance practices for mid-cap biotech firms.
• Vesting schedules of one year are common for annual director equity refreshers in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 9, 2027, or the day before the next annual meeting.

Key Dates

Keywords

ImmunityBio, IBRX, Form 4, Director Compensation, Stock Options, Insider Transaction